Search Results

By Neal S. Chawla, MD, and Sumanta K. Pal, MD, FASCO  / June 10, 2021

Cabozantinib With Nivolumab for Metastatic Renal Cell Carcinoma: A New Front-Line Standard

The pace of clinical research in metastatic renal cell carcinoma is faster than ever. Over the past 5 years, we have seen data from six phase III clinical trials evaluating combination strategies with checkpoint inhibitors. The era began with data from CheckMate 214, evaluating nivolumab with...